FY2026 EPS Estimates for Pharvaris Decreased by Analyst

Pharvaris (NASDAQ:PHVS) – Equities researchers at Leerink Partnrs lowered their FY2026 earnings per share (EPS) estimates for shares of Pharvaris in a research note issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of ($2.87) for the year, down from their previous forecast of ($2.34). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Pharvaris Stock Performance

NASDAQ:PHVS opened at $19.54 on Wednesday. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -6.98 and a beta of -3.06. Pharvaris has a 1 year low of $15.21 and a 1 year high of $33.00. The stock has a fifty day moving average price of $19.40 and a two-hundred day moving average price of $19.35.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio purchased a new stake in Pharvaris during the third quarter worth about $57,000. Barclays PLC acquired a new stake in shares of Pharvaris during the 3rd quarter valued at approximately $106,000. Geode Capital Management LLC boosted its stake in shares of Pharvaris by 18.4% during the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after acquiring an additional 5,753 shares in the last quarter. HighVista Strategies LLC grew its holdings in shares of Pharvaris by 35.9% in the 3rd quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock worth $422,000 after acquiring an additional 6,018 shares during the period. Finally, Jane Street Group LLC purchased a new position in Pharvaris in the 3rd quarter valued at approximately $526,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.